Adlai Nortye to Discuss AN4035 Preclinical Findings at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Treatments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 22 2025
0mins
Should l Buy ANL?
Source: Newsfilter
Presentation Announcement: Adlai Nortye Ltd. will present its novel CEACAM5-targeting antibody-drug conjugate (ADC), AN4035, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston from October 22-26, 2025.
Key Findings: AN4035 showed strong cytotoxicity in specific cancer cell lines, achieved a 73% objective response rate in a patient-derived xenograft trial, and demonstrated a favorable toxicology profile in preclinical studies.
Therapeutic Potential: The ADC is designed to minimize systemic toxicities associated with current pan-RAS(ON) inhibitors, aiming to improve efficacy and broaden the therapeutic window for treating RAS-addicted tumors.
Company Overview: Adlai Nortye is a clinical-stage biotechnology company focused on innovative cancer therapies, with a portfolio that includes next-generation PD-1/L1 modulation and RAS-targeted therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANL
Wall Street analysts forecast ANL stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 16.010
Low
11.00
Averages
11.00
High
11.00
Current: 16.010
Low
11.00
Averages
11.00
High
11.00
About ANL
Adlai Nortye Ltd. is a global clinical-stage biotechnology company. The Company is involved in the research and development of pharmaceutical products. It is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. It is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. It is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor and AN4035, a Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Adlai Nortye Secures $140M in Private Placement Financing
- Financing Size: Adlai Nortye successfully completed a $140 million private placement equity financing through a PIPE transaction, selling approximately 11.32 million ADSs at $13.25 each, reflecting the company's closing price on April 15, 2026, indicating strong market confidence in the financing.
- Use of Proceeds: The funds raised will primarily support ongoing clinical development programs, including RAS-targeting therapies and other cancer treatments, highlighting the company's strategic focus on expanding its oncology pipeline.
- Transaction Timeline: The private placement is expected to close on April 17, 2026, further bolstering investor confidence in the company's future and providing necessary funding for upcoming clinical trials.
- Market Reaction: Following the financing announcement, Adlai Nortye's stock price surged approximately 19% during pre-market trading on Thursday, reflecting a positive market sentiment towards the company's prospects and potentially attracting more investor interest in its shares.
See More
ImmunityBio's Anktiva Receives EU Approval, Boosting Stock
- Anktiva Approval: ImmunityBio (IBRX) received conditional marketing authorization for Anktiva across 33 countries, boosting its market valuation to nearly $6.9 billion with a 287% stock price increase, highlighting its strong growth potential in cancer treatment.
- Adlai Nortye Clinical Progress: Adlai Nortye (ANL) dosed its first U.S. patient in the global AN9025 trial, leading to a 387% stock price surge and a market cap of $216.16 million, indicating significant advancements in its oncology strategy.
- Erasca Global Strategy: Erasca (ERAS) secured worldwide rights to ERAS-0015, resulting in a 335% stock price increase and a market cap exceeding $4.6 billion, reflecting its potential in cancer drug development with promising early clinical responses.
- Investor Sentiment Fluctuations: While IBRX experienced volatile investor sentiment, ANL's shifted from extremely bullish to neutral, and ERAS remained bearish, yet overall interest in these biotech firms increased, indicating sustained market engagement.
See More
Adlai Nortye Shares Show Oversold Signal
- Oversold Indicator Analysis: Adlai Nortye Ltd (Ticker: ANL) hit an RSI of 27.9 during Monday's trading, indicating an oversold condition that suggests the recent heavy selling may be exhausting, prompting investors to consider buying opportunities.
- Price Fluctuation Details: ANL shares traded as low as $6.97, contrasting with a 52-week low of $0.8786 and a high of $12.0899, indicating significant volatility and reflecting drastic market sentiment changes.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 39.7, ANL's oversold status may attract bullish investors, encouraging them to evaluate potential entry points.
- Investor Sentiment Shift: Following recent pressures, ANL's oversold signal could indicate a shift in investor sentiment, and if market conditions improve, the stock price may rebound, presenting investment opportunities.
See More
Adlai Nortye Doses First Patient in AN9025 Clinical Trial
- Clinical Trial Launch: Adlai Nortye successfully dosed the first patient in the U.S. with AN9025, an oral pan-RAS inhibitor, marking a significant milestone in its clinical strategy and expected to drive innovation in cancer treatment.
- Multicenter Trial Design: The Phase 1 clinical trial is designed as a multicenter, open-label study to evaluate the safety and anti-tumor activity of AN9025 in patients with advanced or metastatic solid tumors, demonstrating the company's commitment to advancing cancer therapies globally.
- Partnership Collaboration: Adlai Nortye is conducting this multi-regional clinical trial in collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd., securing market rights in mainland China, Hong Kong, and Macao, which enhances its strategic positioning and partnership capabilities in the Asia-Pacific region.
- R&D Potential: AN9025 has shown potent inhibition against pancreatic, lung, and colorectal adenocarcinomas, indicating its broad application potential in future cancer therapies, which could provide the company with significant competitive advantages in the market.
See More
Adlai Nortye Secures $140M Private Placement Financing
- Significant Financing: Adlai Nortye announced a $140 million private placement equity financing, selling approximately 64.6 million Class A ordinary shares at $2.1667 each, indicating strong market confidence in its innovative therapies.
- Key Investor Support: The placement includes about $55 million of Class A shares sold to entities controlled by Chairman and CEO Yang Lu, demonstrating the management's strong belief in the company's future growth.
- Positive Stock Reaction: Following the financing announcement, Adlai Nortye's stock price surged approximately 25% in pre-market trading on Tuesday, reflecting investor optimism about the company's prospects and potentially attracting further interest.
- Strategic Implications: Yang Lu noted that this financing attracted a high-quality group of healthcare investors to support Adlai Nortye's innovative and potentially best-in-class RAS-targeting therapies, further solidifying the company's market position in the biopharmaceutical sector.
See More
Xpeng Inc Reports Disappointing Delivery Numbers, Stock Drops
- Disappointing Delivery Numbers: Xpeng Inc reported delivering 20,011 vehicles in January 2026, a figure that, while substantial, fell short of market expectations, leading to a decline in investor confidence.
- Stock Price Reaction: Following the disappointing delivery results, Xpeng's stock dropped 5.6% in pre-market trading to $16.97, reflecting concerns about the company's future performance among investors.
- Overall Market Trend: U.S. stock futures were lower, with Dow futures falling around 100 points, indicating a cautious market sentiment that could further impact investor attitudes towards Xpeng.
- Industry Impact: The delivery figures from Xpeng may negatively affect overall confidence in the electric vehicle market, especially in an increasingly competitive landscape, prompting investors to reassess their strategies.
See More
Adlai Nortye Secures $140M in Private Placement Financing
- Financing Size: Adlai Nortye successfully completed a $140 million private placement equity financing through a PIPE transaction, selling approximately 11.32 million ADSs at $13.25 each, reflecting the company's closing price on April 15, 2026, indicating strong market confidence in the financing.
- Use of Proceeds: The funds raised will primarily support ongoing clinical development programs, including RAS-targeting therapies and other cancer treatments, highlighting the company's strategic focus on expanding its oncology pipeline.
- Transaction Timeline: The private placement is expected to close on April 17, 2026, further bolstering investor confidence in the company's future and providing necessary funding for upcoming clinical trials.
- Market Reaction: Following the financing announcement, Adlai Nortye's stock price surged approximately 19% during pre-market trading on Thursday, reflecting a positive market sentiment towards the company's prospects and potentially attracting more investor interest in its shares.
See More
ImmunityBio's Anktiva Receives EU Approval, Boosting Stock
- Anktiva Approval: ImmunityBio (IBRX) received conditional marketing authorization for Anktiva across 33 countries, boosting its market valuation to nearly $6.9 billion with a 287% stock price increase, highlighting its strong growth potential in cancer treatment.
- Adlai Nortye Clinical Progress: Adlai Nortye (ANL) dosed its first U.S. patient in the global AN9025 trial, leading to a 387% stock price surge and a market cap of $216.16 million, indicating significant advancements in its oncology strategy.
- Erasca Global Strategy: Erasca (ERAS) secured worldwide rights to ERAS-0015, resulting in a 335% stock price increase and a market cap exceeding $4.6 billion, reflecting its potential in cancer drug development with promising early clinical responses.
- Investor Sentiment Fluctuations: While IBRX experienced volatile investor sentiment, ANL's shifted from extremely bullish to neutral, and ERAS remained bearish, yet overall interest in these biotech firms increased, indicating sustained market engagement.
See More
Adlai Nortye Shares Show Oversold Signal
- Oversold Indicator Analysis: Adlai Nortye Ltd (Ticker: ANL) hit an RSI of 27.9 during Monday's trading, indicating an oversold condition that suggests the recent heavy selling may be exhausting, prompting investors to consider buying opportunities.
- Price Fluctuation Details: ANL shares traded as low as $6.97, contrasting with a 52-week low of $0.8786 and a high of $12.0899, indicating significant volatility and reflecting drastic market sentiment changes.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 39.7, ANL's oversold status may attract bullish investors, encouraging them to evaluate potential entry points.
- Investor Sentiment Shift: Following recent pressures, ANL's oversold signal could indicate a shift in investor sentiment, and if market conditions improve, the stock price may rebound, presenting investment opportunities.
See More
Adlai Nortye Doses First Patient in AN9025 Clinical Trial
- Clinical Trial Launch: Adlai Nortye successfully dosed the first patient in the U.S. with AN9025, an oral pan-RAS inhibitor, marking a significant milestone in its clinical strategy and expected to drive innovation in cancer treatment.
- Multicenter Trial Design: The Phase 1 clinical trial is designed as a multicenter, open-label study to evaluate the safety and anti-tumor activity of AN9025 in patients with advanced or metastatic solid tumors, demonstrating the company's commitment to advancing cancer therapies globally.
- Partnership Collaboration: Adlai Nortye is conducting this multi-regional clinical trial in collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd., securing market rights in mainland China, Hong Kong, and Macao, which enhances its strategic positioning and partnership capabilities in the Asia-Pacific region.
- R&D Potential: AN9025 has shown potent inhibition against pancreatic, lung, and colorectal adenocarcinomas, indicating its broad application potential in future cancer therapies, which could provide the company with significant competitive advantages in the market.
See More
Adlai Nortye Secures $140M Private Placement Financing
- Significant Financing: Adlai Nortye announced a $140 million private placement equity financing, selling approximately 64.6 million Class A ordinary shares at $2.1667 each, indicating strong market confidence in its innovative therapies.
- Key Investor Support: The placement includes about $55 million of Class A shares sold to entities controlled by Chairman and CEO Yang Lu, demonstrating the management's strong belief in the company's future growth.
- Positive Stock Reaction: Following the financing announcement, Adlai Nortye's stock price surged approximately 25% in pre-market trading on Tuesday, reflecting investor optimism about the company's prospects and potentially attracting further interest.
- Strategic Implications: Yang Lu noted that this financing attracted a high-quality group of healthcare investors to support Adlai Nortye's innovative and potentially best-in-class RAS-targeting therapies, further solidifying the company's market position in the biopharmaceutical sector.
See More
Xpeng Inc Reports Disappointing Delivery Numbers, Stock Drops
- Disappointing Delivery Numbers: Xpeng Inc reported delivering 20,011 vehicles in January 2026, a figure that, while substantial, fell short of market expectations, leading to a decline in investor confidence.
- Stock Price Reaction: Following the disappointing delivery results, Xpeng's stock dropped 5.6% in pre-market trading to $16.97, reflecting concerns about the company's future performance among investors.
- Overall Market Trend: U.S. stock futures were lower, with Dow futures falling around 100 points, indicating a cautious market sentiment that could further impact investor attitudes towards Xpeng.
- Industry Impact: The delivery figures from Xpeng may negatively affect overall confidence in the electric vehicle market, especially in an increasingly competitive landscape, prompting investors to reassess their strategies.
See More
